Overview

AZD6738 Plus Durvalumab in Biliary Tract Cancer

Status:
Recruiting

Trial end date:
2022-03-31

Target enrollment:

Participant gender:

Summary

This trial will enroll advanced biliary tract cancer patients who have been previously treated with immunotherapy in either the 2nd or 3rd line. Patients will be treated with AZD6738 and Durvalumab combination.

Phase:

Phase 2

Details

Lead Sponsor:

Seoul National University Hospital

Treatments:

Antibodies, Monoclonal
Durvalumab